MedTrace Logo

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

NCT02253940 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-10-01

No results posted yet for this study

Summary

Study to determine the single dose, relative BA of new SDS-containing formulations of BILR 355 (150 mg and 200 mg capsules and 150 mg tablet), compared to the current SDS tablet formulation (50 mg tablet)

Conditions

  • Healthy

Interventions

DRUG

BILR 355 - Treatment A (current tablet formulation)

DRUG

BILR 355 - Treatment B (new tablet formulation)

DRUG

BILR 355 - Treatment C (new capsule formulation)

DRUG

BILR 355 - Treatment D (current tablet formulation)

DRUG

BILR 355 - Treatment E (new capsule formulation)

DRUG

Ritonavir

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2006-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02253940 on ClinicalTrials.gov